

## KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma

Sergiu Pasca<sup>1</sup>, Ciprian Tomuleasa<sup>1</sup>, Gabriel Ghiaur<sup>2</sup>, Delia Dima<sup>3</sup>, Vlad Moisoiu<sup>1</sup>, Cristian Berce<sup>1</sup>, Cristina Stefan<sup>4</sup>, Aaron Ciechanover<sup>5</sup>, Hermann Einsele<sup>6</sup>

<sup>1</sup>Iuliu Hațieganu University of Medicine and Pharmacy, Romania, <sup>2</sup>Johns Hopkins University, United States, <sup>3</sup>Oncology Institute Prof. Dr. Ion Chiricuta, Romania, <sup>4</sup>African Organisation for Research and Training in Cancer, South Africa, <sup>5</sup>Rappaport Family Institute for Research in the Medical Sciences, The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Israel, <sup>6</sup>Universitätsklinikum Würzburg, Germany

*Submitted to Journal:*  
Frontiers in Oncology

*Specialty Section:*  
Hematologic Malignancies

*ISSN:*  
2234-943X

*Article type:*  
Hypothesis and Theory Article

*Received on:*  
25 Jul 2019

*Accepted on:*  
10 Oct 2019

*Provisional PDF published on:*  
10 Oct 2019

*Frontiers website link:*  
[www.frontiersin.org](http://www.frontiersin.org)

*Citation:*  
Pasca S, Tomuleasa C, Ghiaur G, Dima D, Moisoiu V, Berce C, Stefan C, Ciechanover A and Einsele H (2019) KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma. *Front. Oncol.* 9:1137. doi:10.3389/fonc.2019.01137